Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEM: SFX-01 in ER+/HER2- Metastatic Breast Cancer
NCT02970682Phase 2Completed
- Sponsor
- TheraCryf
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Biodegradable Polymers, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of sulforadex in breast cancer, sponsored by TheraCryf. Primary endpoints: Treatment-Emergent Adverse Events at 28 weeks and Clinical Benefit Rate at 24 weeks. Started Oct 2016; status: completed.
02
Drugs
sulforadex
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02970682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970682.